Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Bonnie Cao"'
Autor:
Rachel W. Winter, Bonnie Cao, Emily Collins, Anne Marie Crowell, Madeline Carrellas, Joshua R. Korzenik
Publikováno v:
Alimentary Pharmacology & Therapeutics. 45:653-659
SummaryBackground Vitamin D has been linked to disease activity among patients with inflammatory bowel diseases (IBD). Prior investigation has also suggested that vitamin D levels may affect duration of therapy with anti-tumour necrosis factor-α (an
Autor:
Alison Goldin, Anne Marie Crowell, Bonnie Cao, Emily Collins, Madeline Carrellas, Joshua R. Korzenik, Edward L. Barnes, Rachel W. Winter
Publikováno v:
Digestive Diseases and Sciences. 61:3261-3269
The benefits of combination therapy with infliximab and azathioprine have been demonstrated in clinical trials of patients with ulcerative colitis (UC) and Crohn’s disease (CD). Concerns remain regarding the ideal duration and benefits of adding th
Autor:
Joshua R. Korzenik, Danielle Emmons, Brian Vogel, Emily Collins, Lawrence F. Borges, Emily Arthur, Bonnie Cao, Matthew B. Lucci, Matthew S. Chang, Jessica R. Allegretti
Publikováno v:
Inflammatory Bowel Diseases. 21:2583-2589
Background Care of patients with inflammatory bowel disease (IBD) poses a significant burden to the health-care system. Repeat hospitalization in subgroups of IBD patients seems to be a large part of this issue; however, there are limited data examin
Autor:
Jodie Ouahed, Huanyu Zhou, Michael Field, Athos Bousvaros, Lovisa Afzelius, Kenneth E. Hung, Christopher Lepsy, W. Augustine Dunn, Spencer Evans, Sarah Du, Kathleen Phillips, Shelby Friel, William Gordon, Sophia Tollefson, Bwh Crohn’s, Madeline Carrellas, Dror S. Shouval, Ami Merker, Alexandra Griffith, Joshua R. Korzenik, James B. Canavan, Bonnie Cao, Scott B. Snapper, Lu Wang, David von Schack
Publikováno v:
Inflammatory bowel diseases. 24(12)
Background Transcriptional profiling has been performed on biopsies from ulcerative colitis patients. Limitations in prior studies include the variability introduced by inflammation, anatomic site of biopsy, extent of disease, and medications. We sou
Autor:
Bonnie Cao, Marc D. Succi, Joerg Ermann, Laurie H. Glimcher, Jonathan N. Glickman, Joshua R. Korzenik, Allen Zhou, Robert Langer, Giovanni Traverso, Jeffrey M. Karp, Praveen Kumar Vemula, Sufeng Zhang, Matthew J. Hamilton
Publikováno v:
Science Translational Medicine. 7
There is a clinical need for new, more effective treatments for chronic and debilitating inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Targeting drugs selectively to the inflamed intestine may improve therapeutic
Autor:
Madeline Carrellas, Joshua R. Korzenik, Anne Marie Crowell, Shelley Hurwitz, Emily Collins, Edward L. Barnes, Justine States, Bonnie Cao, Ronak V. Patel
Publikováno v:
Gastroenterology. 150:S413-S414
Publikováno v:
Pediatric Transplantation. 22:e13120
Distance from pediatric kidney transplant centers may be a significant barrier in accessing care for patients and families, particularly due to the lower number of pediatric kidney transplant centers compared with the number of adult centers. We perf
Autor:
Faith C. Njoku, Yanik J. Bababekov, David C. Chang, James J. Pomposelli, Heidi Yeh, Ya-Ching Hung, Bonnie Cao, Joel T. Adler
Publikováno v:
Journal of the American College of Surgeons. 225:e78
Autor:
Michael Currier, Beth-Ann Norton, Bonnie Cao, Matthew B. Lucci, Justine States, Emily Collins, Anne Marie Crowell, Madeline Carrellas, Joshua R. Korzenik
Publikováno v:
Gastroenterology. 148:S-255
Background: Vedolizumab, an α4β7 integrin antibody, was recently approved for use in Crohn's disease (CD) and ulcerative colitis (UC). Characteristics of patients with inflammatory bowel disease (IBD) who receive vedolizumab in clinical practice, a
Autor:
Emily Collins, Emily Arthur, Danielle Emmons, Brian Vogel, Joshua R. Korzenik, Matthew S. Chang, Lawrence F. Borges, Jessica R. Allegretti, Bonnie Cao, Matthew B. Lucci
Publikováno v:
Gastroenterology. 148:S-269
Background: Previous studies have demonstrated that the care of inflammatory bowel disease (IBD) patients poses a significant burden to the healthcare system. More than one and a half million people in the United States suffer from ulcerative colitis